HIGHLIGHTS
- What: The authors report on a first-in-human, Phase II trial evaluating safety, immunogenicity and preliminary efficacy of patientindividualized peptide vaccination in CLL after (immuno-) chemotherapy-based first-line therapy, as a proof of concept trial for the feasibility of personalized warehouse-based peptidevaccine design. This trial provides proof of concept for the fast-track immunopeptidome-guided design and production of a personalized multi peptide-vaccine cocktail from an established antigen warehouse for clinical use in CLL patients of various HLA backgrounds. Within this trial the authors further showed that the personalized vaccine product is well . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.